Deciphera Pharmaceuticals (Deciphera Pharmaceuticals) Buildings And Improvements : $0.0 Mil (As of Dec. 2023)

View and export this data going back to 2017. Start your Free Trial

What is Deciphera Pharmaceuticals Buildings And Improvements?

Deciphera Pharmaceuticals Buildings And Improvements Historical Data

The historical data trend for Deciphera Pharmaceuticals's Buildings And Improvements can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Deciphera Pharmaceuticals Buildings And Improvements Chart

Deciphera Pharmaceuticals Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Buildings And Improvements

Get a 7-Day Free Trial

Deciphera Pharmaceuticals Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Buildings And Improvements	Get a 7-Day Free Trial															-	-	-	-	-

Deciphera Pharmaceuticals Buildings And Improvements Calculation

Buildings are typically valued at the time of acquisition or construction. Broker and architect fees, permits, etc. can be covered within this category. Building components, such as a roof, are normally recorded separately in an asset register since the value and useful lives of these components equal much less than the building itself.

Building improvements that extend the useful life of a building will fall into the category of “building improvements” and should be capitalized. Improvements are commonly recorded at acquisition cost. Building improvement examples include roofing, remodeling, replacements, etc.

Deciphera Pharmaceuticals (Deciphera Pharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Deciphera Pharmaceuticals Inc (NAS:DCPH) » Definitions » Buildings And Improvements

Comparable Companies

Traded in Other Exchanges

N/A

Address

200 Smith Street, Waltham, MA, USA, 02451

Website

https://www.deciphera.com

Deciphera Pharmaceuticals Inc is a biotechnology company, which develops and manufactures kinase-inhibiting drugs for the treatment of cancers and immunological diseases. It holds a diverse pipeline of drug candidates that includes three clinical-stage and two research-stage programs. Its lead drug candidate DCC-2618 is designed to inhibit the full spectrum of mutant or amplified KIT and Pdgfra kinases that drive cancers such as gastrointestinal stromal tumors, advanced systemic mastocytosis, gliomas, and other solid tumors. In addition, it is also developing two other clinical-stage drug candidates, DCC-3014 and Rebastinib. Geographically all the operations function through the region of the United States.

Executives

Jama Pitman	officer: SVP, Regulatory & Quality	C/O DECIPHERA PHARMACEUTICALS, INC., 200 SMITH STREET, WALTHAM MA 02451
Daniel C. Martin	officer: Chief Commercial Officer	C/O DECIPHERA PHARMACEUTICALS, INC., 200 SMITH STREET, WALTHAM MA 02451
Thomas Patrick Kelly	officer: Chief Financial Officer	C/O DECIPHERA PHARMACEUTICALS, INC., 200 SMITH STREET, WALTHAM MA 02451
Matthew L Sherman	officer: EVP & Chief Medical Officer	C/O DECIPHERA PHARMACEUTICALS, INC., 200 SMITH STREET, WALTHAM MA 02451
Steven L. Hoerter	director	C/O DECIPHERA PHARMACEUTICALS, INC., 200 SMITH STREET, WALTHAM MA 02451
Dashyant Dhanak	officer: EVP & Chief Scientific Officer	C/O INCYTE CORPORATION, 1801 AUGUSTINE CUT-OFF, WILMINGTON DE 19803
Daniel Lee Flynn	officer: Chief Scientific Officer	C/O DECIPHERA PHARMACEUTICALS, INC., 200 SMITH STREET, WALTHAM MA 02451
Franklin Stuart Friedman	director	C/O DECIPHERA PHARMACEUTICALS, INC., 200 SMITH STREET, WALTHAM MA 02451
Dennis Leo Walsh	director	C/O DECIPHERA PHARMACEUTICALS, INC., 200 SMITH STREET, WALTHAM MA 02451
Brightstar Associates Llc	10 percent owner	1020 CENTRAL STREET, KANSAS CITY MO 64105
James Arthur Bristol	director	C/O DECIPHERA PHARMACEUTICALS, INC., 200 SMITH STREET, WALTHAM MA 02451
Michael Douglas Taylor	director, officer: See Remarks	C/O DECIPHERA PHARMACEUTICALS, LLC, 500 TOTTEN POND ROAD, WALTHAM MA 02451
Patricia L Allen	director	C/O DECIPHERA PHARMACEUTICALS, INC, 200 SMITH STREET, WALTHAM MA 02451
Christopher John Morl	officer: Chief Business Officer	C/O DECIPHERA PHARMACEUTICALS, LLC, 500 TOTTEN POND ROAD, WALTHAM MA 02451
Ron Squarer	director	C/O ADC THERAPEUTICS SA, BIOPOLE, ROUTE DE LA CORNICHE 3B, EPALINGES V8 1066